MGI Tech Co., Ltd. (688114.SS) has a MoatMap StockRank of 19/100 based on Quality (47/100), Value (24/100), and Momentum (34/100) factor scores. The current signal is STRONG SELL. MGI Tech produces DNA sequencing instruments. Despite its advanced technology, it is a primary target of Western geopolitical decoupling efforts (such as the US Biosecure Act), creating severe structural headwinds for its international expansion.
MGI Tech Co., Ltd. manufactures high-throughput gene sequencers, laboratory automation systems, and related reagents. The company is one of the very few companies globally possessing proprietary DNBSEQ sequencing technology, breaking Illumina's near-monopoly in genetic sequencing. It is a high-tech life science instrument leader with a strong global IP portfolio and expanding international market share.
| Price | $6.75 |
| Market Cap | $3.1B |
| P/E (Forward) | 391.10 |
| Price/Book | 2.89 |
| Return on Equity | -2.1% |
| Return on Invested Capital | -2.9% |
| Debt/Equity | 16.98 |
| Gross Margin | 48.8% |
| Operating Margin | -6.3% |
| Revenue Growth | 24.8% |
| Free Cash Flow | $8M |
MGI Tech Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (China).